Welcome to our dedicated page for ICON PLC SEC filings (Ticker: ICLR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ICON plc filings document current-report disclosures for a foreign private issuer in the clinical research organization sector. Form 6-K reports furnish press releases and exhibits on operating results, financial guidance, earnings-call scheduling, conference presentations, shareholder voting matters, governance updates, and clinical or regulatory disclosures.
The filings also record accounting-practices and internal-control matters, including revenue-recognition disclosures, as well as XBRL financial information covering operating results, equity accounts and reporting-segment data. These documents frame ICON’s public-company reporting around clinical development services, capital structure, governance and risk-related material events.
ICON plc plans to release financial results for the second quarter 2026 after the market closes on Wednesday, July 29, 2026. A conference call and webcast to discuss the results and business performance is scheduled for Thursday, July 30, 2026 at 8:00am ET, with a replay available about one hour after the call.
ICON is described as a world-leading clinical research organization providing consulting, clinical development, commercialization and post-marketing solutions to life sciences and public health customers globally. As of March 31, 2026, it employed approximately 40,350 people across 97 locations in 55 countries. The company includes forward-looking statements language outlining risks such as reliance on pharmaceutical clients, industry competition, execution of projects, regulatory changes, exchange-rate movements, inflation and rising labor costs.
ICON plc has convened its Annual General Meeting for 31 July 2026 and is asking shareholders to re-elect all ten directors, approve the 2025 audited accounts and renew authorities to issue up to 20% of share capital and repurchase up to 10% until 30 January 2028.
The company discloses an Audit Committee investigation into certain accounting practices, which led to restatements of 2023–2024 clinical trial services revenue and profit; 2024 revenue was reduced by $92.7 million to $8,189.0 million and profit by $52.3 million. For 2025, revenue rose 0.8% to $8,251.3 million, but operating profit including exceptional items fell to $427.1 million due to a $367.6 million goodwill impairment, $101.0 million of other asset impairments, a $12.0 million onerous contract provision and $104.3 million of restructuring and transaction costs.
ICON redeemed 4,504,330 shares for $750.0 million in 2025 and still has $750.0 million of repurchase authorisation. It refinanced debt with $2.0 billion of new senior secured notes in 2024, reduced term-loan interest margins and added a $500 million Bridge Secured Credit Facility in April 2026 to address upcoming note maturities.
ICON plc reported mixed first quarter 2026 results. Revenue was $2.03 billion, up 0.9% year over year, but down 1.9% on a constant currency basis, showing only modest top-line growth. GAAP net income was $104.8 million, with diluted earnings per share of $1.36 versus $1.99 a year earlier.
Profitability softened, with adjusted EBITDA of $317.7 million, or 15.6% of revenue, a 20.2% decline on quarter one 2025. Adjusted net income was $192.9 million, or $2.50 per share, down from $3.27. However, commercial performance remained strong, with net business wins of $2.88 billion, a book-to-bill of 1.42, and backlog of $22.7 billion.
ICON generated $167.0 million in operating cash flow and $136.2 million in free cash flow, ending the quarter with $765.2 million in cash and net debt of $2.6 billion, implying net debt to adjusted EBITDA of 1.8x. The company reaffirmed its 2026 guidance, targeting revenue between $7.85 billion and $8.15 billion and adjusted diluted EPS between $10.00 and $11.00.
ICON plc, a global clinical research organization based in Dublin, plans to release its first quarter 2026 financial results after the market closes on Tuesday, June 23, 2026. The company will host a conference call and webcast to discuss results on Wednesday, June 24, 2026 at 8:00am ET, with access and any updates available in the Investor section of its website.
ICON describes itself as a world-leading clinical research organization providing integrated consulting, clinical development, commercialization and post-marketing solutions to life sciences, government and public health clients worldwide. As of December 31, 2025, it employed approximately 40,100 employees across 97 locations in 55 countries.
ICON PLC director Kevin Francis Egan filed an initial Form 3, which is a statement of beneficial ownership for insiders. This filing lists him as a director of ICON PLC but does not report any stock transactions or current holdings in the provided data.
ICON PLC director Jeffrey Thomas Elliott has filed an initial Form 3 reporting no insider transactions or holdings. The filing identifies him as a director of ICON PLC but shows no reported common stock or derivative positions and no recent purchases, sales, or other equity transactions.
ICON plc reported modest growth for 2025 but sharply lower earnings alongside a completed accounting investigation and financial restatements. Fourth quarter 2025 revenue was $2,112.5 million, up 2.5% year over year, with adjusted EBITDA of $327.1 million (15.5% margin). Full year 2025 revenue reached $8,251.3 million, up 0.8%, while GAAP net income declined to $229.3 million or $2.90 diluted EPS versus $8.90 a year earlier. Adjusted net income was $989.8 million or $12.53 per share, down 6.3%.
Net business wins in 2025 were $9,033 million with a book-to-bill of 1.09 and year-end backlog of $21.8 billion under a refined cancellations and backlog methodology. Free cash flow was strong at $862.0 million, supporting $750.0 million of share repurchases and reducing net debt to $2.8 billion, 1.8x adjusted EBITDA.
The Audit Committee’s investigation into certain accounting practices is complete. ICON is restating prior years after determining revenue was overstated by $65.3 million in 2023 and $92.7 million in 2024, and has identified material weaknesses in internal control over financial reporting. Management has begun a remediation plan. For 2026, ICON guides to revenue of $7,850–$8,150 million and adjusted diluted EPS of $10.00–$11.00.
ICON plc is restating its unaudited quarterly financial statements for March, June and September in 2023, 2024 and 2025 after an investigation into revenue recognition and related estimates. The restatement adjusts clinical trial services revenue, unbilled revenue and accounts receivable, and updates tax and balance sheet items.
For the three months ended September 30, 2025, goodwill impairment increased to $364.2 million and an additional $101.0 million impairment of non-financial assets was recorded, turning previously reported net income of $2.4 million into a net loss of $284.2 million. The Data Solutions reporting unit accounts for the goodwill and intangible impairments.
Earlier quarters see more modest revenue and profit revisions, with some periods revised downward and others upward, but overall retained earnings and total assets are reduced across the restated periods. Management also details geographic and customer concentration trends, with Ireland-sourced revenue growing strongly while U.S. revenue declined in early 2025.
ICON plc is restating prior-year results and disclosing control failures in its latest annual report. After an audit committee investigation into revenue recognition, the company restated its 2023–2024 financial statements, reducing 2024 revenue by 1.1% and 2023 revenue by 0.8% versus prior reports.
Net income was cut by $52.3M for 2024 and $58.1M for 2023, lowering diluted EPS to $8.90 in 2024 and $6.70 in 2023. Management concluded disclosure controls and internal control over financial reporting were not effective as of December 31, 2025 due to material weaknesses and is undertaking remediation.
ICON also recorded a $364.2M goodwill impairment in 2025 and continues to carry substantial debt, with total debt of $3,416.7M and shareholders’ equity of $9,193.4M at year-end 2025.